CIPLA.BO - Cipla Limited

BSE - BSE Real Time Price. Currency in INR
638.15
+3.55 (+0.56%)
As of 12:45PM IST. Market open.
Stock chart is not supported by your current browser
Previous close634.60
Open637.00
Bid638.15 x 0
Ask638.50 x 0
Day's range635.40 - 642.50
52-week range356.75 - 696.00
Volume80,631
Avg. volume316,671
Market cap514.522B
Beta (5Y monthly)0.41
PE ratio (TTM)33.31
EPS (TTM)19.16
Earnings date06-Aug-2019 - 10-Aug-2019
Forward dividend & yield6.00 (0.95%)
Ex-dividend date19-Mar-2020
1y target estN/A
  • India's Hetero prices experimental COVID-19 drug remdesivir at $71 per 100 mg vial
    Reuters

    India's Hetero prices experimental COVID-19 drug remdesivir at $71 per 100 mg vial

    India's Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at 5,400 rupees ($71) per 100-milligram vial, the drugmaker said on Wednesday, as it prepares to ship them to hospitals in the country. The privately held company said it would supply 20,000 vials of the drug. Fellow Indian drug firm Cipla Ltd had said on Tuesday that its own version of the antiviral drug remdesivir would be priced below 5,000 rupees.

  • Cipla to price remdesivir version for COVID-19 under 5,000 rupees
    Reuters

    Cipla to price remdesivir version for COVID-19 under 5,000 rupees

    Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said. Cipla and privately held Indian drugmaker Hetero Labs on Sunday gained approval to sell generic versions of remdesivir in the country. Hetero expects to price a similar 100 milligram dose of the treatment at 5,000 to 6,000 rupees.

  • India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug
    Reuters

    India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug

    The drug, which will be marketed under the brand name Covifor, will likely be priced at 5,000 to 6,000 rupees ($66-$79) for a 100 milligram dose, Hetero said. India's Cipla said its generic version of remdesivir will be called Cipremi. The Drug Controller General of India (DCGI) was not immediately available for comment.